AI Article Synopsis
- This study investigates how critical illness affects the effectiveness of β-lactam antibiotics in treating hospital-acquired pneumonia.
- Researchers analyzed plasma data from 70 patients treated with meropenem to determine how often desired pharmacokinetic/pharmacodynamic (PK/PD) goals were met.
- Results showed significant variability in meeting targets, indicating that personalized treatment strategies are necessary for critically ill patients.
Article Abstract
Objectives: Critical illness reduces β-lactam pharmacokinetic/pharmacodynamic (PK/PD) attainment. We sought to quantify PK/PD attainment in patients with hospital-acquired pneumonia.
Methods: Meropenem plasma PK data (n = 70 patients) were modelled, PK/PD attainment rates were calculated for empirical and definitive targets, and between-patient variability was quantified [as a coefficient of variation (CV%)].
Results: Attainment of 100% T>4×MIC was variable for both empirical (CV% = 92) and directed (CV% = 33%) treatment.
Conclusions: Individualization is required to achieve suggested PK/PD targets in critically ill patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205601 | PMC |
| http://dx.doi.org/10.1093/jac/dkac245 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!